Skip to content
The People's CodeSearch
Menu

21 U.S.C. § 360bbb–8b · 21, 360bbb–8b of the Federal Food, Drug, and Cosmetic Act § 569B

§ 360bbb–8b. Use of clinical investigation data from outside the United States

(a) In general In determining whether to approve, license, or clear a drug, biological product, or device pursuant to an application submitted under this subchapter, the Secretary shall accept data from clinical investigations conducted outside of the United States, including the European Union, if the applicant demonstrates that such data are adequate under applicable standards to support approval, licensure, or clearance of the drug, biological product, or device in the United States.

(b) Notice to sponsor If the Secretary finds under subsection (a) that the data from clinical investigations conducted outside the United States, including in the European Union, are inadequate for the purpose of making a determination on approval, clearance, or licensure of a drug, biological product, or device pursuant to an application submitted under this subchapter, the Secretary shall provide written notice to the sponsor of the application of such finding and include the rationale for such finding.

Where this text comes from

The public laws () that wrote and changed it, and where each is printed in the Statutes at Large ().

(June 25, 1938, ch. 675, § 569B, as added Pub. L. 112–144, title XI, § 1123, July 9, 2012, 126 Stat. 1113; amended Pub. L. 114–255, div. A, title III, § 3101(a)(2)(Q), Dec. 13, 2016, 130 Stat. 1155.)

Notes (1)

Editorial Notes

Amendments

2016—Pub. L. 114–255 substituted “drug, biological product, or device” for “drug or device” wherever appearing.

Would change this section

No bill we know of would change this section.

Versions

Each is an official edition of the Code (a ), up to date through the named.

  • Through Public Law 119-138, Current